Fresenius Medical Care (FMS) reported Q2 adjusted earnings Tuesday of 0.91 euro ($1.05) per share, up from 0.72 euro a year earlier.
Revenue for the quarter ended June 30 was 4.79 billion euros, compared with 4.77 billion euros a year earlier.
Analysts polled by FactSet expected 4.93 billion euros.
For fiscal 2025, the company reaffirmed its guidance for positive to low single-digit percent revenue growth year over year. Analysts surveyed by FactSet expect revenue of 19.55 billion euros.
Shares of the company were down more than 1% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.